TEVA.N Teva Pharmaceutical Industries Limited Sponsored ADR

Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025

Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025

TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2025 financial results on Wednesday, May 7, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.

In order to participate, please register in advance  to obtain a local or toll-free phone number and your personal pin.

A live webcast of the call will be available on Teva's website at: .

Following the conclusion of the call, a replay of the webcast will be available within 24 hours on Teva's website.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of global biopharmaceutical leader, one that operates across the full spectrum of innovation to deliver medicines to patients worldwide. For over 120 years, Teva’s commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its 37,000 employees across 57 markets to advance health by developing medicines for the future while championing the production of generics and biologics. We are dedicated to addressing patients’ needs, now and in the future. Moving forward together with science that treats, inspired by the people we serve. To learn more about how Teva is all in for better health, visit .

Cautionary Note Regarding Forward-Looking Statements

This press release and the conference call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace including our ability to successfully execute our Pivot to Growth strategy; our significant indebtedness; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in this press release, in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the sections captioned "Risk Factors” and "Forward-looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.



EN
27/03/2025

Underlying

Reports on Teva Pharmaceutical Industries Limited Sponsored ADR

 PRESS RELEASE

Teva und Prestige Biopharma schließen Lizenzvereinbarung für die Verma...

Teva und Prestige Biopharma schließen Lizenzvereinbarung für die Vermarktung von Tuznue® in Europa Teva und Prestige geben eine Lizenz- und Liefervereinbarung für die Vermarktung des von Prestige hergestellten Arzneimittels Tuznue® bekannt, einem Biosimilar zu Herceptin® (trastuzumab)Die Europäische Kommission (EK) erteilte Tuznue® im September 2024 die MarktzulassungDie Partnerschaft vereint das Know-how beider Unternehmen im Bereich Biosimilars TEL AVIV, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, eine Tochtergesellschaft von Teva Pharmaceutical I...

 PRESS RELEASE

Teva et Prestige Biopharma concluent un accord de licence pour la comm...

Teva et Prestige Biopharma concluent un accord de licence pour la commercialisation de Tuznue® en Europe Teva et Prestige annoncent un accord de licence et d’approvisionnement pour la commercialisation de Tuznue®, un biosimilaire d’Herceptin® (trastuzumab) produit par PrestigeTuznue® a reçu l’autorisation de mise sur le marché de la Commission européenne (CE) en septembre 2024Ce partenariat conjugue l’expertise des deux entreprises dans le domaine des biosimilaires TEL AVIV, Israël, 21 oct. 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, une filiale de Teva Pharmaceutic...

 PRESS RELEASE

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commer...

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe Teva and Prestige announce a license and supply agreement for the commercialization of Prestige’s Tuznue®, a biosimilar to Herceptin® (trastuzumab) Tuznue® received European Commission (EC) marketing authorization in September 2024Partnership brings together both companies’ expertise in biosimilars TEL AVIV, Israel, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) entered into a license agreement w...

Felix Fischer
  • Felix Fischer

Europe HY Trade Book - Healthcare - Lucror Analytics

The Europe HY Trade Book - Healthcare includes current trade recommendations drawn from our European HY healthcare coverage universe, along with relative-value scatter plots and a peer table.

Felix Fischer
  • Felix Fischer

Europe HY Trade Book - Healthcare - Lucror Analytics

The Europe HY Trade Book - Healthcare includes current trade recommendations drawn from our European HY healthcare coverage universe, along with relative-value scatter plots and a peer table. 

ResearchPool Subscriptions

Get the most out of your insights

Get in touch